Principles of treatment for osteosarcoma

Endicott, M. M.

doi:10.1053/svms.2003.36626

Cited by 18 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os cães machos são diagnosticados com osteossarcoma 1,1 a 2 vezes mais frequentes que as fêmeas (Endicott, 2003). No Brasil não se tem uma estatística a respeito das principais raças acometidas, suas respectivas faixas etárias e localização do osteossarcoma.…”

Section: Resultsunclassified

Canine osteosarcoma: Case report

Lima¹,

Gomes²,

Negreiros³

et al. 2017

Pubvet

View full text Add to dashboard Cite

RESUMO.Osteossarcoma é um dos tumores ósseos maligno mais comum em cães, sendo que nessa espécie mais de 80% das neoplasias ósseas malignas são osteossarcomas. A ocorrência desta doença é maior em cães com 5 a 9 anos, com pico ao redor de 7 anos, porém ela também pode ser observada em cães jovens, com 1 ano de idade. Em raças de grande porte a incidência é maior e ambos os sexos são igualmente acometidos. O osteossarcoma ocorre também em gatos, mas é menos comum do que em cães, e o desenvolvimento de metástases é mais lento. A etiologia do osteossarcoma canino permanece desconhecida. Os primeiros sintomas a serem observados são claudicação e extenso aumento de volume, doloroso, no foco tumoral. O diagnóstico é baseado no histórico, exame físico, laboratorial, citilográficos e principalmente achados radiográficos, que mostram áreas de destruição óssea, neoformação óssea, contorno indefinido, reação periosteal (em alguns casos em "raios de sol") e aumento do volume de tecidos moles, sendo a confirmação feita por biópsia e exame histopatológico. Os tratamentos podem ser com quimioterapia, radioterapia, cirurgia para a amputação do membro acometido e cirurgia com preservação de membro. O prognóstico em geral é ruim, porém dependerá da espécie, da raça e da resposta ao tratamento. Palavras chave: Neoplasia óssea, osteossarcoma, tumor ósseoCanine osteosarcoma: Case report ABSTRACT. Osteosarcoma is one of the most common malignant bone tumors in dogs, and in this species more than 80% of malignant bone neoplasms are osteosarcomas. The occurrence of this disease is greater in dogs with 5 to 9 years, with a peak around 7 years, but it can also be observed in young dogs, at 1 year of age. In large breeds the incidence is higher and both sexes are equally affected. Osteosarcoma also occurs in cats, but is less common than in dogs, and the development of metastases is slower. The etiology of canine osteosarcoma remains unknown. The first symptoms to be observed are lameness and extensive painful volume increase in the tumor focus. The diagnosis is based on the history, physical examination, laboratory examination, scintigraphy and mainly radiographic findings, showing areas of bone destruction, bone neoformation, indefinite contour, periosteal reaction (in some cases in "sun rays") and increase in tissue volume The biopsy and histopathological examination were confirmed. The treatments can be with chemotherapy, radiotherapy, surgery for amputation of the affected limb and surgery with limb preservation. The prognosis is usually poor, but will depend on the species, the breed and the response to treatment.

show abstract

Section: Resultsunclassified

Canine osteosarcoma: Case report

Lima¹,

Gomes²,

Negreiros³

et al. 2017

Pubvet

View full text Add to dashboard Cite

show abstract

“…94,95,[98][99][100] Metastatic disease is often subclinical and only apparent radiographically in < 15% of patients at initial examination. 94,95,[98][99][100] Treatment can be intensive and often Small Animals includes adjunctive therapy because approximately 90% of patients die of metastatic disease within 1 year when amputation is the only treatment. 94,95,[98][99][100] Large-and giant-breed dogs are at greater risk of developing osteosarcoma.…”

Section: Small Animalsmentioning

confidence: 99%

“…94,95,[98][99][100] Treatment can be intensive and often Small Animals includes adjunctive therapy because approximately 90% of patients die of metastatic disease within 1 year when amputation is the only treatment. 94,95,[98][99][100] Large-and giant-breed dogs are at greater risk of developing osteosarcoma. 10,16,94,98,99 Gonadectomy may also contribute to a higher risk of developing osteosarcoma.…”

Section: Small Animalsmentioning

confidence: 99%

“…93 Osteosarcoma is the most common primary malignant bone tumor of dogs. 16,[94][95][96][97][98][99] Osteosarcoma is locally aggressive and frequently has early metastasis, most often to pulmonary structures. 94,95,[98][99][100] Metastatic disease is often subclinical and only apparent radiographically in < 15% of patients at initial examination.…”

Section: Small Animalsmentioning

confidence: 99%

“…16,[94][95][96][97][98][99] Osteosarcoma is locally aggressive and frequently has early metastasis, most often to pulmonary structures. 94,95,[98][99][100] Metastatic disease is often subclinical and only apparent radiographically in < 15% of patients at initial examination. 94,95,[98][99][100] Treatment can be intensive and often Small Animals includes adjunctive therapy because approximately 90% of patients die of metastatic disease within 1 year when amputation is the only treatment.…”

Section: Small Animalsmentioning

confidence: 99%

See 2 more Smart Citations

A literature review on the welfare implications of gonadectomy of dogs

Houlihan¹

2017

javma

View full text Add to dashboard Cite

Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients

Agarwal

Gammon

Sandey

et al. 2021

Heliyon

View full text Add to dashboard Cite

Osteosarcoma is one among the most common neoplasms in dogs. Current treatments show limited efficacy and fail to prevent metastasis. Conditionally replicative adenoviruses (CRAd) replicate exclusively in targeted tumor cells and release new virus particles to infect additional cells. We proposed that OC-CAVE1 (CAV2 with the E1A promoter replaced with the osteocalcin promotor) may also enhance existing immunity against tumors by overcoming immune tolerance via exposure of new epitopes and cytokine signaling. Eleven client-owned dogs with spontaneously occurring osteosarcomas were enrolled in a pilot study. All dogs were injected with OC-CAVE1 following amputation of the affected limb or limb-sparing surgery. Dogs were monitored for viremia and viral shedding. There was minimal virus shedding in urine and feces by the 6th day and no virus was present in blood after 4 weeks. CAV-2 antibody-titers increased in all of the patients, post-CRAd injection. Immunological assays were performed to monitor 1) humoral response against tumors, 2) levels of circulatory CD11c + cells, 3) levels of regulatory T cells, and 4) cytotoxic activity of tumor specific T cells against autologous tumor cells between pre-CRAd administration and 4 weeks post-CRAd administration samples. Administration of the CRAd OC-CAVE1 resulted in alteration of some immune response parameters but did not appear to result in increased survival duration. However, 2 dogs in the study achieved survival times in excess of 1 year. Weak replication of OC-CAVE1 in metastatic cells and delay of chemotherapy following CRAd treatment may contribute to the lack of immune response and improvement in survival time of the clinical patients.

show abstract

Principles of treatment for osteosarcoma

Cited by 18 publications

References 15 publications

Canine osteosarcoma: Case report

Canine osteosarcoma: Case report

A literature review on the welfare implications of gonadectomy of dogs

Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients

Contact Info

Product

Resources

About